Skip to main content

News

Firm News

Mayer Brown advises Bristol-Myers Squibb on $74 billion acquisition of Celgene

3 January 2019
Mayer Brown provided intellectual property counsel to Bristol-Myers Squibb in its $74 billion acquisition of Celgene.

The transaction will create a premier innovative biopharma company with complementary portfolios focused on treating patients with cancer, inflammatory and immunologic disease and cardiovascular disease. The combined company will have expanded capabilities in the areas of small molecule design, biologics, antibody engineering and cell therapy. The transaction is expected to close in the third quarter of 2019.

The Mayer Brown Intellectual Property team included partners Lisa Ferri and Brian Nolan and associate Elliot Choi.

Related Information

  • Related People
    Lisa M. Ferri
    T +1 212 506 2340
    Brian W. Nolan
    T +1 212 506 2517
    Elliot Choi
    Associate
    T +1 212 506 2235
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.